Biopharma Catalyst Calendar
Forward-looking catalysts for the world's largest pharmaceutical and biotech companies — FDA PDUFA target dates, advisory-committee (AdCom) meetings, and Phase 2/3 clinical-trial readout windows. Trial timing is sourced from ClinicalTrials.gov; each row links to its public source. Updated every few hours.
For informational purposes only — not investment advice. Primary-completion dates are estimates and can precede the investable readout. Open the live Mooboard dashboard →
Companies
This week26
- Sep 23, 2026ClinicalTrials.gov ↗PF-07220060 · Phase 2 · Liposarcoma; Prostate CancerNCT04557449: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors. Primary completion 2026-09-23 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 24, 2026ClinicalTrials.gov ↗YTB323 · Phase 1 / Phase 2 · Systemic Lupus Erythematosus; Lupus NephritisNCT05798117: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus. Primary completion 2026-09-24 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 24, 2026ClinicalTrials.gov ↗IBI362 · Phase 2 · Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF)NCT06862908: A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity. Primary completion 2026-09-24 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 26, 2026ClinicalTrials.gov ↗Zibotentan/Dapagliflozin · Phase 2 · Chronic Kidney Disease With High ProteinuriaNCT06942910: A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria. Primary completion 2026-09-26 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 27, 2026ClinicalTrials.gov ↗Litifilimab · Phase 3 · Lupus Erythematosus, SystemicNCT04961567: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus. Primary completion 2026-09-27 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 28, 2026ClinicalTrials.gov ↗AZD0901 · Phase 2 · Gastric Cancer; Gastroesophageal Junction CancerNCT07143604: A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2. Primary completion 2026-09-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 28, 2026ClinicalTrials.gov ↗INCB099280 · Phase 2 · Cutaneous Squamous Cell CarcinomaNCT05888844: A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma. Primary completion 2026-09-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 29, 2026ClinicalTrials.gov ↗Amlitelimab · Phase 2 · AsthmaNCT06033833: Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study. Primary completion 2026-09-29 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Entrectinib · Phase 3 · Carcinoma, Non-Small-Cell LungNCT04603807: A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Placebo · Phase 2 · DyslipidaemiaNCT07218900: A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Durvalumab · Phase 3 · Hepatocellular CarcinomaNCT05557838: Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Durvalumab · Phase 3 · Non-Small Cell Lung CancerNCT05221840: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Dato-DXd · Phase 3 · Metastatic Non-small Cell Lung CancerNCT06417814: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Primary completion 2026-09-30 (estimated); status RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Iptacopan (LNP023) · Phase 2 · Age-Related Macular DegenerationNCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗JDQ443 · Phase 1 / Phase 2 · KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell LungNCT05358249: Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗balinatunfib · Phase 2 · Colitis Ulcerative; Crohn's DiseaseNCT07222189: A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS). Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗BMS-986449 · Phase 1 / Phase 2 · Advanced Solid TumorsNCT05888831: A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Litifilimab · Phase 3 · Lupus Erythematosus, SystemicNCT04895241: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Ifinatamab deruxtecan · Phase 1 / Phase 2 · Extensive Stage-small Cell Lung CancerNCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03). Primary completion 2026-09-30 (estimated); status RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Staccato alprazolam · Phase 3 · Stereotypical Prolonged SeizuresNCT05077904: A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures. Primary completion 2026-09-30 (estimated); status RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗INCB099280 · Phase 2 · Advanced Solid TumorNCT05879822: A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Zanidatamab · Phase 3 · Gastric Neoplasms; Gastroesophageal AdenocarcinomaNCT05152147: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Pemetrexed · Phase 3 · Non-Small Cell Lung CancerNCT05116462: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗IBI363+IBI305 · Phase 2 · EGFR Mutant NSCLC and Platinum Resistant Ovarian CancerNCT07124793: A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors. Primary completion 2026-09-30 (estimated); status NOT_YET_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Tirzepatide · Phase 1 / Phase 2 · ObesityNCT07000955: Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Dextromethorphan and Bupropion Sustained-Release Tablets · Phase 3 · Major Depressive Disorder (MDD)NCT06958692: A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder. Primary completion 2026-09-30 (estimated); status RECRUITING.
Next 30 days46
- Oct 2026ClinicalTrials.gov ↗Retatrutide · Phase 3 · Type 2 DiabetesNCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3). Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Baricitinib · Phase 3 · Systemic Juvenile Idiopathic ArthritisNCT04088396: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA). Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 1, 2026ClinicalTrials.gov ↗Ziltivekimab · Phase 3 · Heart Failure; Systemic InflammationNCT06200207: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation. Primary completion 2026-10-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Aflibercept (EYLEA®) · Phase 3 · AMD; nAMDNCT05407636: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD. Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗AGN-151586 · Phase 2 · Forehead LinesNCT07730554: A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Sacituzumab Govitecan-hziy · Phase 2 · Solid TumorNCT05119907: Study of Sacituzumab Govitecan in Patients With Solid Tumor. Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 1, 2026ClinicalTrials.gov ↗efgartigimod PH20 SC · Phase 3 · Primary Immune ThrombocytopeniaNCT04812925: A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia. Primary completion 2026-10-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗SHR-A2102 for Injection · Phase 1 / Phase 2 · Advanced or Metastatic Non-small Cell Lung CancerNCT06512051: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗HRS-9821 Inhalation Suspension · Phase 2 · COPDNCT07640451: A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗SHR-A2102；Adebrelimab；Cisplatin · Phase 1 / Phase 2 · Advanced or Metastatic Esophageal CancerNCT06474468: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗SHR-A2102 · Phase 2 · Non-small Cell Lung CancerNCT07229729: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Sirolimus for Injection (Albumin-bound) · Phase 3 · HR+/HER2- Advanced/Metastatic Breast CancerNCT06929325: Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors. Primary completion 2026-10 (estimated); status NOT_YET_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗D-1553 Tablet · Phase 3 · Non Small Cell Lung CancerNCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2, 2026ClinicalTrials.gov ↗TAK-861 · Phase 3 · Narcolepsy Type 1 (NT1); Narcolepsy With CataplexyNCT07363720: A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy. Primary completion 2026-10-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 5, 2026ClinicalTrials.gov ↗KarXT · Phase 3 · Psychosis Associated With Alzheimer's DiseaseNCT05511363: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1). Primary completion 2026-10-05 (estimated); status RECRUITING.
- Oct 5, 2026ClinicalTrials.gov ↗mRNA-1189 · Phase 1 / Phase 2 · Epstein-Barr Virus InfectionNCT05164094: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults. Primary completion 2026-10-05 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 5, 2026ClinicalTrials.gov ↗rozanolixizumab · Phase 2 / Phase 3 · Generalized Myasthenia GravisNCT06149559: A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis. Primary completion 2026-10-05 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 6, 2026ClinicalTrials.gov ↗BMS-986278 · Phase 3 · Idiopathic Pulmonary FibrosisNCT06003426: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis. Primary completion 2026-10-06 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 7, 2026ClinicalTrials.gov ↗AZD6489 · Phase 1 / Phase 2 · RSV Respiratory Syncytial VirusNCT07717840: A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES). Primary completion 2026-10-07 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 7, 2026ClinicalTrials.gov ↗Dupilumab · Phase 3 · Atopic DermatitisNCT02612454: Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Primary completion 2026-10-07 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 8, 2026ClinicalTrials.gov ↗Tobemstomig · Phase 2 · Renal Cell CarcinomaNCT05805501: A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma. Primary completion 2026-10-08 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 8, 2026ClinicalTrials.gov ↗Hydroxocobalamin Chloride Injection · Phase 3 · Methylmalonic Acidemia (MMA)NCT07163364: A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type). Primary completion 2026-10-08 (estimated); status NOT_YET_RECRUITING.
- Oct 9, 2026ClinicalTrials.gov ↗Ruxolitinib Cream · Phase 3 · Hidradenitis SuppurativaNCT06959225: Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1). Primary completion 2026-10-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 9, 2026ClinicalTrials.gov ↗Ruxolitinib Cream · Phase 3 · Hidradenitis SuppurativaNCT06958211: Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2). Primary completion 2026-10-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 11, 2026ClinicalTrials.gov ↗HB1801 · Phase 2 · Advanced Breast CancerNCT07083505: A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer. Primary completion 2026-10-11 (estimated); status NOT_YET_RECRUITING.
- Oct 12, 2026ClinicalTrials.gov ↗Apalutamide · Phase 3 · Metastatic Castrate-sensitive Prostate CancerNCT05884398: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC. Primary completion 2026-10-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 12, 2026ClinicalTrials.gov ↗CC-92480 · Phase 1 / Phase 2 · Multiple MyelomaNCT05372354: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma. Primary completion 2026-10-12 (estimated); status RECRUITING.
- Oct 12, 2026ClinicalTrials.gov ↗Ravulizumab · Phase 3 · Paroxysmal Nocturnal HemoglobinuriaNCT05133531: A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment. Primary completion 2026-10-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 14, 2026ClinicalTrials.gov ↗Atezolizumab · Phase 3 · Unresectable Hepatocellular CarcinomaNCT04770896: A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab. Primary completion 2026-10-14 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 14, 2026ClinicalTrials.gov ↗Itepekimab (SAR440340) · Phase 3 · Chronic Rhinosinusitis With Nasal PolypsNCT06834347: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps. Primary completion 2026-10-14 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 15, 2026ClinicalTrials.gov ↗Milvexian · Phase 3 · Ischemic Stroke; Ischemic Attack, TransientNCT05702034: A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE. Primary completion 2026-10-15 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 15, 2026ClinicalTrials.gov ↗AAA617 · Phase 2 · Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT06894511: An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC. Primary completion 2026-10-15 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 16, 2026ClinicalTrials.gov ↗Glofitamab · Phase 1 / Phase 2 · Non-Hodgkins LymphomaNCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. Primary completion 2026-10-16 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Tobemstomig · Phase 2 · Breast CancerNCT05852691: A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer. Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗PF-07275315 · Phase 2 · Atopic DermatitisNCT05995964: A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis. Primary completion 2026-10-19 (estimated); status RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Deucravacitinib · Phase 3 · Systemic Lupus ErythematosusNCT05617677: A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Deucravacitinib · Phase 3 · Systemic Lupus ErythematosusNCT05620407: A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus. Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Povorcitinib · Phase 3 · Prurigo NodularisNCT06516952: A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Povorcitinib · Phase 3 · Prurigo NodularisNCT06516965: A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 20, 2026ClinicalTrials.gov ↗Litifilimab · Phase 2 / Phase 3 · Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus ErythematosusNCT05531565: A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus. Primary completion 2026-10-20 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 20, 2026ClinicalTrials.gov ↗DS-3939a · Phase 1 / Phase 2 · Advanced Solid Tumor; Metastatic Solid TumorNCT05875168: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors. Primary completion 2026-10-20 (estimated); status RECRUITING.
- Oct 20, 2026ClinicalTrials.gov ↗SEP-363856 · Phase 3 · SchizophreniaNCT06894212: A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia. Primary completion 2026-10-20 (estimated); status RECRUITING.
- Oct 22, 2026ClinicalTrials.gov ↗Ocrelizumab · Phase 3 · Progressive Multiple Sclerosis (PMS)NCT03523858: A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis. Primary completion 2026-10-22 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 22, 2026ClinicalTrials.gov ↗Belzutifan · Phase 1 / Phase 2 · Renal Cell CarcinomaNCT05468697: A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024). Primary completion 2026-10-22 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 22, 2026ClinicalTrials.gov ↗Dazodalibep · Phase 3 · Sjögren's Syndrome (SS)NCT06245408: A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State. Primary completion 2026-10-22 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 23, 2026ClinicalTrials.gov ↗Durvalumab · Phase 2 · Carcinoma, Non-Small-Cell LungNCT06008093: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS. Primary completion 2026-10-23 (estimated); status ACTIVE_NOT_RECRUITING.
31–90 days48
- Oct 26, 2026ClinicalTrials.gov ↗Inclisiran sodium 300 mg · Phase 3 · Coronary Artery DiseaseNCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events. Primary completion 2026-10-26 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 26, 2026ClinicalTrials.gov ↗Recombinant single-chain factor VIII (rVIII-SingleChain) · Phase 3 · Congenital Hemophilia ANCT06738485: Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products. Primary completion 2026-10-26 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 27, 2026ClinicalTrials.gov ↗Volrustomig · Phase 2 · Hepatocellular Carcinoma; Biliary Tract CancerNCT05775159: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer. Primary completion 2026-10-27 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 28, 2026ClinicalTrials.gov ↗RO7204239 · Phase 2 / Phase 3 · Spinal Muscular Atrophy (SMA)NCT05115110: A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy. Primary completion 2026-10-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 28, 2026ClinicalTrials.gov ↗Belzutifan · Phase 3 · Carcinoma, Renal CellNCT05239728: A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022). Primary completion 2026-10-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 29, 2026ClinicalTrials.gov ↗Ianalumab · Phase 3 · Primary Immune Thrombocytopenia (ITP)NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP). Primary completion 2026-10-29 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 30, 2026ClinicalTrials.gov ↗Encorafenib · Phase 3 · MelanomaNCT04657991: A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma. Primary completion 2026-10-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 30, 2026ClinicalTrials.gov ↗venglustat (GZ402671) · Phase 2 · Gaucher Disease Type 1; Gaucher Disease Type 3NCT02843035: Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension. Primary completion 2026-10-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 30, 2026ClinicalTrials.gov ↗VX-121/TEZ/D-IVA · Phase 3 · Cystic FibrosisNCT05444257: A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy. Primary completion 2026-10-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 30, 2026ClinicalTrials.gov ↗Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR · Phase 3 · Type 2 DiabetesNCT07026968: A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes. Primary completion 2026-10-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 31, 2026ClinicalTrials.gov ↗Capivasertib · Phase 3 · Breast CancerNCT06635447: Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 31, 2026ClinicalTrials.gov ↗anvumetostat · Phase 2 · MTAP-deleted NSCLCNCT06593522: A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201). Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 31, 2026ClinicalTrials.gov ↗TAK-788 · Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT04129502: TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 31, 2026ClinicalTrials.gov ↗TAK-788 · Phase 1 / Phase 2 · Carcinoma, Non-Small-Cell LungNCT02716116: A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 31, 2026ClinicalTrials.gov ↗SHR6390 · Phase 3 · Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast CancerNCT04842617: Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 31, 2026ClinicalTrials.gov ↗TEV-56248 · Phase 3 · AsthmaNCT06052267: A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 31, 2026ClinicalTrials.gov ↗IBI3003 · Phase 1 / Phase 2 · Multiple MyelomaNCT06083207: A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma. Primary completion 2026-10-31 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Tirzepatide · Phase 3 · Type 1 Diabetes; ObesityNCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗LY3938577 · Phase 2 · Diabetes Mellitus, Type 2NCT07215312: A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗LY4515100 · Phase 2 · Acute Pain; MolarNCT07511816: A Study of LY4515100 in Participants With Pain Following Third Molar Removal. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Retatrutide · Phase 3 · ObesityNCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Tirzepatide · Phase 3 · Type 1 Diabetes; ObesityNCT06962280: A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Venetoclax · Phase 2 · Chronic Lymphocytic Leukemia (CLL)NCT04895436: Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL). Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Budigalimab · Phase 2 · Hepatocellular CarcinomaNCT05822752: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC). Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗ABBV-932 · Phase 2 · Generalized Anxiety Disorder (GAD)NCT06846320: Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Mirvetuximab soravtansine · Phase 2 · High Grade Ovarian Cancer; Primary Peritoneal CancerNCT05456685: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 1, 2026ClinicalTrials.gov ↗KarXT · Phase 3 · Bipolar-I Disorder With Mania or Mania With Mixed FeaturesNCT06951698: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder. Primary completion 2026-11-01 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Empasiprubart IV · Phase 2 · Dermatomyositis; MyositisNCT06284954: A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗RO7198457 intravenous (IV) · Phase 2 · Colorectal Cancer Stage II; Colorectal Cancer Stage IIINCT04486378: A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗SHR-A1811 combined with Pyrotinib. · Phase 1 / Phase 2 · HER2-expressing Advanced Solid TumorsNCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗HRS-8427 · Phase 3 · Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)NCT06569056: A Trial of HRS-8427 in the Treatment of Adults With Complicated Urinary Tract Infection, Including Acute Pyelonephritis. Primary completion 2026-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗Bupivacaine Liposome Injection · Phase 2 · Local Analgesia Via Nerve BlockNCT06529432: A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗NTQ5082 capsules 200 mg · Phase 3 · Paroxysmal Nocturnal HemoglobinuriaNCT07177859: A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients. Primary completion 2026-11 (estimated); status NOT_YET_RECRUITING.
- Nov 2026ClinicalTrials.gov ↗TQH2722 injection · Phase 2 · Seasonal Allergic RhinitisNCT07398859: Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2026ClinicalTrials.gov ↗TQB2868 injection · Phase 2 · Pancreatic NeoplasmsNCT06767813: Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms. Primary completion 2026-11 (estimated); status RECRUITING.
- Nov 2, 2026ClinicalTrials.gov ↗Anifrolumab · Phase 3 · Cutaneous Lupus ErythematosusNCT06015737: A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus. Primary completion 2026-11-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 2, 2026ClinicalTrials.gov ↗KarXT · Phase 3 · Bipolar Disorder Type I With Mania or Mania With Mixed FeaturesNCT06951711: A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2). Primary completion 2026-11-02 (estimated); status RECRUITING.
- Nov 2, 2026ClinicalTrials.gov ↗cemiplimab · Phase 2 · MelanomaNCT06190951: A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma. Primary completion 2026-11-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 3, 2026ClinicalTrials.gov ↗LOU064 (blinded) · Phase 3 · Chronic Spontaneous UrticariaNCT05677451: 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up. Primary completion 2026-11-03 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 5, 2026ClinicalTrials.gov ↗Fitusiran · Phase 3 · HemophiliaNCT03754790: Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX. Primary completion 2026-11-05 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 5, 2026ClinicalTrials.gov ↗Parsaclisib · Phase 2 · B-Cell MalignanciesNCT04509700: Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465). Primary completion 2026-11-05 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 6, 2026ClinicalTrials.gov ↗pembrolizumab · Phase 2 · Hodgkin LymphomaNCT03407144: Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667). Primary completion 2026-11-06 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 6, 2026ClinicalTrials.gov ↗Itepekimab (SAR440340) · Phase 3 · Chronic Rhinosinusitis With Nasal PolypsNCT06834360: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps. Primary completion 2026-11-06 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 11, 2026ClinicalTrials.gov ↗Trastuzumab deruxtecan · Phase 3 · Breast Cancer; HER2-positive; MetastaticNCT04784715: Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09). Primary completion 2026-11-11 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 13, 2026ClinicalTrials.gov ↗Inavolisib · Phase 3 · Breast CancerNCT05646862: A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy. Primary completion 2026-11-13 (estimated); status RECRUITING.
- Nov 13, 2026ClinicalTrials.gov ↗REGN7075 · Phase 1 / Phase 2 · Advanced Solid TumorsNCT04626635: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers. Primary completion 2026-11-13 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 13, 2026ClinicalTrials.gov ↗Olatorepatide · Phase 2 · Overweight or ObesityNCT07431086: Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US. Primary completion 2026-11-13 (estimated); status ACTIVE_NOT_RECRUITING.
- Nov 16, 2026ClinicalTrials.gov ↗Zilucoplan · Phase 2 / Phase 3 · Generalized Myasthenia GravisNCT06055959: A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis. Primary completion 2026-11-16 (estimated); status RECRUITING.